Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Novira Therapeutics

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

World Hepatitis Day highlights need to reach 2030 elimination target

According to the World Hepatitis Alliance, someone dies from a viral hepatitis-related illness every 30 seconds

- PMLiVE

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’...

Avalere Health

- PMLiVE

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

Darzalex treatment regimen reduced risk of death by 32% after nearly five years follow-up

- PMLiVE

J&J exits $1.6bn blood cancer drug licensing deal with argenx

J&J and argenx signed a deal in 2018 to develop cusatuzumab to treat haematological cancers

- PMLiVE

J&J’s single-dose COVID-19 vaccine secures approval from the UK’s MHRA

Vaccine was found to be 67% effective in preventing COVID-19 infection in a phase 3 study

- PMLiVE

FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine

Vaccine candidate demonstrated an overall efficacy of 66% in phase 3

- PMLiVE

Gilead set to acquire hepatitis specialist MYR for €1.15bn

Acquisition will see Gilead pick up HDV treatment Hepcludex

- PMLiVE

Vaccine developers call on FDA to offer clarity on COVID-19 trials

Comments from J&J and Pfizer made before FDA advisory committee meeting yesterday

- PMLiVE

J&J signs deal with EU for 200 million COVID-19 vaccine doses

EU member states will have an option to secure 200 million additional doses

- PMLiVE

J&J says COVID-19 vaccine could be ready in early 2021

Also receives US federal backing to increase manufacturing for the shot

- PMLiVE

J&J aims for US approval of MS drug ponesimod

Files application with FDA in relapsing form of the disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links